BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7529853)

  • 1. Biomarkers associated with prostate cancer progression.
    Zhau HE; Pisters LL; Hall MC; Zhao LS; Troncoso P; Pollack A; Chung LW
    J Cell Biochem Suppl; 1994; 19():208-16. PubMed ID: 7529853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfected neu oncogene induces human prostate cancer metastasis.
    Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
    Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-met proto-oncogene expression in benign and malignant human prostate tissues.
    Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
    J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene.
    Sikes RA; Chung LW
    Cancer Res; 1992 Jun; 52(11):3174-81. PubMed ID: 1350510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
    Jackson MW; Roberts JS; Heckford SE; Ricciardelli C; Stahl J; Choong C; Horsfall DJ; Tilley WD
    Cancer Res; 2002 Feb; 62(3):854-9. PubMed ID: 11830543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
    Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
    Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
    Thalmann GN; Anezinis PE; Chang SM; Zhau HE; Kim EE; Hopwood VL; Pathak S; von Eschenbach AC; Chung LW
    Cancer Res; 1994 May; 54(10):2577-81. PubMed ID: 8168083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and prostate cancer: identification of a molecular progression switch.
    Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
    Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines.
    Webber MM; Bello D; Quader S
    Prostate; 1996 Dec; 29(6):386-94. PubMed ID: 8977636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
    McAlhany SJ; Ressler SJ; Larsen M; Tuxhorn JA; Yang F; Dang TD; Rowley DR
    Cancer Res; 2003 Sep; 63(18):5859-65. PubMed ID: 14522910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
    Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
    Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.